+86(1812)4514114 info@phcoker.com

Raw Leuprorelin Acetate powder (74381-53-6)

Leuprorelin Acetate powder is a synthetic nonapeptide that is a potent gonadotropin-releasing hormone receptor (GnRHR)…..


Status: In Mass Production
Synthesized and Customized Available
Capacity: 1277kg/month

 

Description

Raw Leuprorelin Acetate powder (74381-53-6) video

 

Raw Leuprorelin Acetate powder (74381-53-6) Description

Leuprorelin Acetate powder is a synthetic nonapeptide that is a potent gonadotropin-releasing hormone receptor (GnRHR) agonist used for diverse clinical applications, including the treatment of prostate cancer, endometriosis, uterine fibroids, central precocious puberty and in vitro fertilization techniques. As its basic mechanism of action, Raw Leuprorelin Acetate powder (74381-53-6) suppresses gonadotrope secretion of luteinizing hormone and follicle-stimulating hormone that subsequently suppresses gonadal sex steroid production.

Raw Leuprorelin Acetate powder (74381-53-6) Specifications

Product Name Leuprorelin Acetate powder
Chemical Name Leuprolide acetate,74381-53-6, Leuprorelin acetate, Lupron, Enantone
Brand Name Eligard
Drug Class Peptide
CAS Number 74381-53-6
InChIKey RGLRXNKKBLIBQS-XNHQSDQCSA-N
Molecular Formula C59H84N16O12.C2H4O2
Molecular Weight 1269.46
Monoisotopic Mass 1269.5
Melting Point  150-155°C
Biological Half-Life N/A
Color N/A
Solubility  <6.24mg/mL in DMSO
Storage Temperature  −20°C
Application the treatment of prostate cancer, endometriosis, uterine fibroids, central precocious puberty and in vitro fertilization techniques.

 


=

References & product citations

The key information of leuprorelin acetate side effect, dosage

 

References

  1. Song, G., Gao, H., & Yuan, Z. (2013). Effect of leuprolide acetate on ovarian function after cyclophosphamide–doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial. Medical oncology30(3), 667.
  2. Köhler, G., Faustmann, T. A., Gerlinger, C., Seitz, C., & Mueck, A. O. (2010). A dose‐ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis. International Journal of Gynecology & Obstetrics108(1), 21-25.
  3. Tunn, U. W., Gruca, D., & Bacher, P. (2013). Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation. Clinical interventions in aging8, 457.
  4. Johnson, S. R., Nolan, R. C., Grant, M. T., Price, G. J., Siafarikas, A., Bint, L., & Choong, C. S. (2012). Sterile abscess formation associated with depot leuprorelin acetate therapy for central precocious puberty. Journal of paediatrics and child health48(3), E136-E139.